ClinicalTrials.gg

Program

MC-1-50

Its studies are mostly in Lupus Erythematosus, Systemic · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, B-Cell, led by Chongqing Precision Biotech.

Furthest: phase 1, since Dec 12, 20233 company-led studies, 3 open or runningNext primary completion: Nov 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Precision Biotech33 open or runningphase 1since Dec 12, 2023Dec 12, 2023Nov 1, 2027phase 1 · NCT06641024

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2023First study: phase 1 study in Lymphoma, B-CellFirst studyNCT06180174 · 24 planned · China
  2. Sep 27, 2024Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06641024 · 24 planned · China
  3. Mar 18, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06892145 · 12 planned · China

Ahead

  1. Nov 1, 2027Primary completion: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06641024

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06892145Lupus Erythematosus, Systemic · China1RecruitingMay 4, 202612
NCT06641024Precursor Cell Lymphoblastic Leukemia-Lymphoma · China1Not yet recruitingNov 1, 202724
NCT06180174Lymphoma, B-Cell · China1RecruitingDec 31, 202524

How it is read

Names in the registry

  • “MC-1-50”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.